Joshua A Halpern1, Art Sedrakyan1, Brian Dinerman1, Wei-Chun Hsu1, Jialin Mao1, Jim C Hu2. 1. Department of Urology, Weill Cornell Medical College, New York, New York; Department of Healthcare Policy and Research (AS, WCH), Weill Cornell Medical College, New York, New York. 2. Department of Urology, Weill Cornell Medical College, New York, New York; Department of Healthcare Policy and Research (AS, WCH), Weill Cornell Medical College, New York, New York. Electronic address: jch9011@med.cornell.edu.
Abstract
PURPOSE: Uptake of active surveillance and changes in prostate cancer care may affect the utilization of and complications following prostate needle biopsy. We characterized recent trends and risk factors for prostate needle biopsy complications using a statewide, all-payer cohort. MATERIALS AND METHODS: We used SPARCS (New York Statewide Planning and Research Cooperative System) to identify prostate needle biopsies performed between 2011 and 2014 via the transrectal and the transperineal approach (9,472 and 421 patients, respectively). We characterized trends in utilization and complications using Poisson regression and the Cochrane-Armitage test. We applied logistic regression to examine predictors of complications within 30 days of prostate needle biopsy. RESULTS: Ambulatory use of prostate needle biopsy decreased with time (p <0.01). The most common indication for prostate needle biopsy was elevated prostate specific antigen in 53.2% of patients, followed by active surveillance for cancer in 26.7%, abnormal digital rectal examination in 2.6% and atypia in 1.6%. The prostate needle biopsy associated infection rate increased from 2.6% to 3.5% during the study period (p = 0.02). Among the 777 repeat prostate needle biopsies, the complication rate was comparable to that of initial prostate needle biopsy. Preprocedural rectal swab was done in less than 1% of prostate needle biopsies. On multivariable analysis, patient race, procedure year, diabetes (OR 1.92, 95% CI 1.29-2.86, p <0.01), transrectal approach (OR 3.48, 95% CI 1.27-9.54, p = 0.02) and recent hospitalization (OR 2.03, 95% CI 1.43-2.89, p <0.01) were significantly associated with infection. The median total charge for infectious complications was $4,129 (IQR 711-19,185). CONCLUSIONS: Across New York State, infectious complications after prostate needle biopsy have increased over time. With higher complications using the transrectal approach and minimal utilization of targeted antibiotic prophylaxis, further efforts should focus on the evaluation and implementation of these strategies to reduce post-prostate needle biopsy complications nationally.
PURPOSE: Uptake of active surveillance and changes in prostate cancer care may affect the utilization of and complications following prostate needle biopsy. We characterized recent trends and risk factors for prostate needle biopsy complications using a statewide, all-payer cohort. MATERIALS AND METHODS: We used SPARCS (New York Statewide Planning and Research Cooperative System) to identify prostate needle biopsies performed between 2011 and 2014 via the transrectal and the transperineal approach (9,472 and 421 patients, respectively). We characterized trends in utilization and complications using Poisson regression and the Cochrane-Armitage test. We applied logistic regression to examine predictors of complications within 30 days of prostate needle biopsy. RESULTS: Ambulatory use of prostate needle biopsy decreased with time (p <0.01). The most common indication for prostate needle biopsy was elevated prostate specific antigen in 53.2% of patients, followed by active surveillance for cancer in 26.7%, abnormal digital rectal examination in 2.6% and atypia in 1.6%. The prostate needle biopsy associated infection rate increased from 2.6% to 3.5% during the study period (p = 0.02). Among the 777 repeat prostate needle biopsies, the complication rate was comparable to that of initial prostate needle biopsy. Preprocedural rectal swab was done in less than 1% of prostate needle biopsies. On multivariable analysis, patient race, procedure year, diabetes (OR 1.92, 95% CI 1.29-2.86, p <0.01), transrectal approach (OR 3.48, 95% CI 1.27-9.54, p = 0.02) and recent hospitalization (OR 2.03, 95% CI 1.43-2.89, p <0.01) were significantly associated with infection. The median total charge for infectious complications was $4,129 (IQR 711-19,185). CONCLUSIONS: Across New York State, infectious complications after prostate needle biopsy have increased over time. With higher complications using the transrectal approach and minimal utilization of targeted antibiotic prophylaxis, further efforts should focus on the evaluation and implementation of these strategies to reduce post-prostate needle biopsy complications nationally.
Authors: Neel H Patel; Suraj S Parikh; Jonathan B Bloom; Ariel Schulman; Jonathan Wagmaister; Sean Fullerton; John L Phillips; Muhammad Choudhury; Majid Eshghi Journal: J Endourol Date: 2019-07-23 Impact factor: 2.942
Authors: Julie Y An; Abhinav Sidana; Sarah A Holzman; Joseph A Baiocco; Sherif Mehralivand; Peter L Choyke; Bradford J Wood; Baris Turkbey; Peter A Pinto Journal: Int Urol Nephrol Date: 2017-11-15 Impact factor: 2.370
Authors: Matthew J Roberts; Alastair Macdonald; Sachinka Ranasinghe; Harrison Bennett; Patrick E Teloken; Patrick Harris; David Paterson; Geoff Coughlin; Nigel Dunglison; Rachel Esler; Robert A Gardiner; Thomas Elliott; Louisa Gordon; John Yaxley Journal: Prostate Cancer Prostatic Dis Date: 2020-08-05 Impact factor: 5.554
Authors: Michael Davenport; Kathleen E Mach; Linda M Dairiki Shortliffe; Niaz Banaei; Tza-Huei Wang; Joseph C Liao Journal: Nat Rev Urol Date: 2017-03-01 Impact factor: 14.432
Authors: Hormuzd A Katki; Amanda Black; Rebecca Landy; Lauren C Houghton; Christine D Berg; Robert L Grubb Journal: Cancer Prev Res (Phila) Date: 2020-01-29
Authors: Jesse F Wang; Margaret A Knoedler; Kimberly A Maciolek; Natasza M Posielski; Vania Lopez; Wade A Bushman; Sara L Best; Dan R Gralnek; Kyle A Richards Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Susan Scott; Patrick N Harris; Deborah A Williamson; Michael A Liss; Suhail A R Doi; Matthew J Roberts Journal: World J Urol Date: 2018-02-16 Impact factor: 4.226
Authors: Tyler J Nelson; Juan Javier-DesLoges; Rishi Deka; P Travis Courtney; Vinit Nalawade; Loren Mell; James Murphy; J Kellogg Parsons; Brent S Rose Journal: JAMA Netw Open Date: 2021-05-03
Authors: Michael Ahdoot; Amir H Lebastchi; Lori Long; Andrew R Wilbur; Patrick T Gomella; Sherif Mehralivand; Michael A Daneshvar; Nitin K Yerram; Luke P O'Connor; Alex Z Wang; Sandeep Gurram; Jonathan Bloom; M Minhaj Siddiqui; W Marston Linehan; Maria Merino; Peter L Choyke; Paul Pinsky; Howard Parnes; Joanna H Shih; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: Eur Urol Oncol Date: 2021-04-10